Table 3. Open in new tab Marginal...

ART Class	Person-years	Incident Number	Crude HR (95% CI)	IPTW^a IPCW Weighted Marginal Structural Model, HR (95% CI)
Ratio CD4/CD8 ≥0.3
INSTI + 2 NRTIs	230.3	349	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	313.5	243	.48 (.39–.59)	.52 (.36–.75)
PI + 2 NRTIs	427.9	388	.55 (.46–.66)	.57 (.40–.80)
Ratio CD4/CD8 ≥0.5
INSTI + 2 NRTIs	326.9	321	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	454.2	222	.48 (.39–.58)	0.51 (.37–.69)
PI + 2 NRTIs	730.0	333	.44 (.36–.52)	.43 (.32–.58)
Ratio CD/CD8 ≥0.8
INSTIs + 2 NRTIs	545.1	257	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	695.8	180	.55 (.45–.67)	.56 (.44–.72)
PIs + 2 NRTIs	1210.6	222	.37 (.31–.45)	.38 (.30–.47)
Ratio CD4/CD8 ≥1
INSTIs + 2 NRTIs	696.2	204	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	833.3	142	.59 (.47–.74)	.60 (.47–.77)
PIs + 2 NRTIs	1386.5	166	.40 (.32–.50)	.41 (.32–.51)
Ratio CD4/CD8 ≥1.2
INSTIs + 2 NRTIs	815.9	159	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	960.4	109	.59 (.46–.76)	.61 (.47–.79)
PIs + 2 NRTIs	1569.54	111	.36 (.28–.46)	.39 (.30–.50)

ART Class

Person-years

Incident Number

Crude HR (95% CI)

IPTW^a IPCW Weighted Marginal Structural Model, HR (95% CI)

Ratio CD4/CD8 ≥0.3

INSTI + 2 NRTIs

230.3

349

1 (reference)

NNRTI + 2 NRTIs

313.5

243

.48 (.39–.59)

.52 (.36–.75)

PI + 2 NRTIs

427.9

388

.55 (.46–.66)

.57 (.40–.80)

Ratio CD4/CD8 ≥0.5

INSTI + 2 NRTIs

326.9

321

1 (reference)

NNRTI + 2 NRTIs

454.2

222

.48 (.39–.58)

0.51 (.37–.69)

PI + 2 NRTIs

730.0

333

.44 (.36–.52)

.43 (.32–.58)

Ratio CD/CD8 ≥0.8

INSTIs + 2 NRTIs

545.1

257

1 (reference)

NNRTIs + 2 NRTIs

695.8

180

.55 (.45–.67)

.56 (.44–.72)

PIs + 2 NRTIs

1210.6

222

.37 (.31–.45)

.38 (.30–.47)

Ratio CD4/CD8 ≥1

INSTIs + 2 NRTIs

696.2

204

1 (reference)

NNRTIs + 2 NRTIs

833.3

142

.59 (.47–.74)

.60 (.47–.77)

PIs + 2 NRTIs

1386.5

166

.40 (.32–.50)

.41 (.32–.51)

Ratio CD4/CD8 ≥1.2

INSTIs + 2 NRTIs

815.9

159

1 (reference)

NNRTIs + 2 NRTIs

960.4

109

.59 (.46–.76)

.61 (.47–.79)

PIs + 2 NRTIs

1569.54

111

.36 (.28–.46)

.39 (.30–.50)

ART Class	Person-years	Incident Number	Crude HR (95% CI)	IPTW^a IPCW Weighted Marginal Structural Model, HR (95% CI)
Ratio CD4/CD8 ≥0.3
INSTI + 2 NRTIs	230.3	349	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	313.5	243	.48 (.39–.59)	.52 (.36–.75)
PI + 2 NRTIs	427.9	388	.55 (.46–.66)	.57 (.40–.80)
Ratio CD4/CD8 ≥0.5
INSTI + 2 NRTIs	326.9	321	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	454.2	222	.48 (.39–.58)	0.51 (.37–.69)
PI + 2 NRTIs	730.0	333	.44 (.36–.52)	.43 (.32–.58)
Ratio CD/CD8 ≥0.8
INSTIs + 2 NRTIs	545.1	257	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	695.8	180	.55 (.45–.67)	.56 (.44–.72)
PIs + 2 NRTIs	1210.6	222	.37 (.31–.45)	.38 (.30–.47)
Ratio CD4/CD8 ≥1
INSTIs + 2 NRTIs	696.2	204	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	833.3	142	.59 (.47–.74)	.60 (.47–.77)
PIs + 2 NRTIs	1386.5	166	.40 (.32–.50)	.41 (.32–.51)
Ratio CD4/CD8 ≥1.2
INSTIs + 2 NRTIs	815.9	159	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	960.4	109	.59 (.46–.76)	.61 (.47–.79)
PIs + 2 NRTIs	1569.54	111	.36 (.28–.46)	.39 (.30–.50)

Table 3.

Open in new tab

Marginal Structural Cox Model Estimates for the Effect of the Third Active Class in Antiretroviral Therapy on CD4/CD8 Ratio Among Treatment-Naive Patients Receiving a First Treatment Only

ART Class	Person-years	Incident Number	Crude HR (95% CI)	IPTW^a IPCW Weighted Marginal Structural Model, HR (95% CI)
Ratio CD4/CD8 ≥0.3
INSTI + 2 NRTIs	230.3	349	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	313.5	243	.48 (.39–.59)	.52 (.36–.75)
PI + 2 NRTIs	427.9	388	.55 (.46–.66)	.57 (.40–.80)
Ratio CD4/CD8 ≥0.5
INSTI + 2 NRTIs	326.9	321	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	454.2	222	.48 (.39–.58)	0.51 (.37–.69)
PI + 2 NRTIs	730.0	333	.44 (.36–.52)	.43 (.32–.58)
Ratio CD/CD8 ≥0.8
INSTIs + 2 NRTIs	545.1	257	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	695.8	180	.55 (.45–.67)	.56 (.44–.72)
PIs + 2 NRTIs	1210.6	222	.37 (.31–.45)	.38 (.30–.47)
Ratio CD4/CD8 ≥1
INSTIs + 2 NRTIs	696.2	204	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	833.3	142	.59 (.47–.74)	.60 (.47–.77)
PIs + 2 NRTIs	1386.5	166	.40 (.32–.50)	.41 (.32–.51)
Ratio CD4/CD8 ≥1.2
INSTIs + 2 NRTIs	815.9	159	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	960.4	109	.59 (.46–.76)	.61 (.47–.79)
PIs + 2 NRTIs	1569.54	111	.36 (.28–.46)	.39 (.30–.50)

ART Class	Person-years	Incident Number	Crude HR (95% CI)	IPTW^a IPCW Weighted Marginal Structural Model, HR (95% CI)
Ratio CD4/CD8 ≥0.3
INSTI + 2 NRTIs	230.3	349	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	313.5	243	.48 (.39–.59)	.52 (.36–.75)
PI + 2 NRTIs	427.9	388	.55 (.46–.66)	.57 (.40–.80)
Ratio CD4/CD8 ≥0.5
INSTI + 2 NRTIs	326.9	321	1 (reference)	1 (reference)
NNRTI + 2 NRTIs	454.2	222	.48 (.39–.58)	0.51 (.37–.69)
PI + 2 NRTIs	730.0	333	.44 (.36–.52)	.43 (.32–.58)
Ratio CD/CD8 ≥0.8
INSTIs + 2 NRTIs	545.1	257	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	695.8	180	.55 (.45–.67)	.56 (.44–.72)
PIs + 2 NRTIs	1210.6	222	.37 (.31–.45)	.38 (.30–.47)
Ratio CD4/CD8 ≥1
INSTIs + 2 NRTIs	696.2	204	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	833.3	142	.59 (.47–.74)	.60 (.47–.77)
PIs + 2 NRTIs	1386.5	166	.40 (.32–.50)	.41 (.32–.51)
Ratio CD4/CD8 ≥1.2
INSTIs + 2 NRTIs	815.9	159	1 (reference)	1 (reference)
NNRTIs + 2 NRTIs	960.4	109	.59 (.46–.76)	.61 (.47–.79)
PIs + 2 NRTIs	1569.54	111	.36 (.28–.46)	.39 (.30–.50)

N = 1041. Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; INSTI, integrase strand transfer inhibitor; IPCW, inverse probability of censoring weights; IPTW, inverse probability of treatment weights; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Weighted variables: age (continuous), delay in ART treatment initiation (continuous), and nadir CD4 (<200, 200–350 and >350 cells/mm³). CD4, CD8, and viral load variables (continuous) were considered time-dependent during follow-up.

This Feature Is Available To Subscribers Only